登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688177 证券简称：百奥泰 公告编号：2026-010 百奥泰生物制药股份有限公司 关于GotenfiaR（戈利木单抗注射液）获欧洲EMA上市批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于近日收到欧洲药品管理局（以下简 称"EMA"）签发的关于GotenfiaR（BAT2506，戈利木单抗注射液）上市批准通知。 GotenfiaR作为百奥泰又一个获得EMA上市批准的产品，将进一步拓展公司国际化市场，提升公司产品 的国际影响力，有望对公司长期经营业绩产生积极影响。已上市竞品和其他潜在竞品可能会拥有先行者 优势，GotenfiaR可能在未来面临激烈的市场竞争。 考虑到医药产品具有高科技、高风险、高附加值的特点，药品的前期研发以及产品从研制、临床试验报 批到投产的周期长，易受到技术、审批、政策等多方面因素的影响，未来产品市场竞争形势均存在诸多 不确定性，敬请广大投资者谨慎决策，注意投资风险，公 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、担保情况概述 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000935 证券简称：四川双马 公告编号：2026-3 四川和谐双马股份有限公司 关于控股子公司之间提供担保的公告 注册资本：25,342万人民币 四川和谐双马股份有限公司（简称"公司"或"上市公司"）的控股子公司湖北健翔生物制药有限公司（简 称"湖北健翔"）因生产经营需要，拟向交通银行股份有限公司申请人民币贰亿元的八年期固定资产贷款 额度。该贷款额度主要用于多肽药物扩建项目建设。 湖北健翔为公司控股子公司深圳市健元医药科技有限公司（简称"深圳健元"）的全资子公司，深圳健元 将与交通银行股份有限公司（简称"交通银行"）签订《保证合同》。该《保证合同》约定，深圳健元将 基于前述贷款为湖北健翔向交通银行提供担保，担保方式为连带责任保证。担保范围包括但不限于本 金、利息、违约金、损害赔偿金及相关费用等。同时，待具备抵押条件后，湖北健翔将就前述贷款向交 通银行提供该扩建项目固定资产及相关设备的抵押担保。 该担保事项已经深圳健元董事会审议通过， ...

Summary of Soleno Therapeutics Conference Call Company Overview - **Company**: Soleno Therapeutics (NasdaqCM:SLNO) - **Industry**: Rare Disease Biopharmaceuticals - **Product**: First approved treatment for Prader-Willi syndrome (PWS), a genetic disorder characterized by hyperphagia, with no prior treatments available [5][38] Key Points and Arguments Market Position and Growth Expectations - Soleno currently holds approximately **10%** of the total addressable market (TAM) with a target of reaching another **10%** over the next **9-12 months**, equating to about **250 Start Forms** per quarter [7][12] - The company anticipates moving from Start Forms to traditional metrics of revenue and active patients after the first quarter of 2026 [10] - The expectation is that the holiday variability seen in the previous quarter will not recur, as there are no major holidays in the current quarter [8] Patient Flow and Revenue Generation - The process for Start Forms involves a **30-45 day** assessment period through their specialty pharmacy partner, Panther, with a small percentage of forms being canceled [14] - The discontinuation rate for patients is expected to stabilize between **15%-20%**, which is considered healthy for a rare disease context [15][24] - Active patient revenue is driven by a combination of paid and free patients, with adherence impacting overall revenue [17][18] Financial Guidance and Revenue Trends - Soleno is not providing full-year guidance for 2026 as the business is still maturing [11] - The company expects a **seasonal increase** in Gross to Net discounts in the first quarter due to resets in copay and potential changes in patient coverage [20][21] - The overall discontinuation rate as of the fourth quarter was approximately **15%**, with **12%** being adverse event-related [23] Clinical and Market Insights - Adverse events (AEs) reported in the real-world setting are consistent with those observed in clinical trials, primarily non-serious [26] - Most patients are titrating to their prescribed doses, with a few exceptions due to comorbidities [27][28] - The average wholesale acquisition cost (WAC) is currently in the **$500,000s**, with expectations of gradual increases over the next few years [31][32] Market Expansion and Reimbursement - Soleno has coverage for approximately **185 million lives**, with expectations for this number to increase as reimbursement policies improve [42] - The company is experiencing a favorable reimbursement environment, with no significant issues reported regarding prior authorizations [44] - There is a growing number of prescribers, with over **600** currently, which exceeds initial expectations [41] International Opportunities - The company is preparing for potential CHMP approval in Europe, with an estimated patient population of **9,500** in the EU and UK [47] - Soleno is considering launching the product independently in Europe while also exploring partnership opportunities [49] Capital Deployment Strategy - Soleno plans to focus on sustaining the success of its launch and exploring other indications, while also considering inorganic growth opportunities [50] Additional Important Insights - The company acknowledges the challenges of educating prescribers unfamiliar with PWS and the drug, which is crucial for improving treatment outcomes [45] - There is a noted social aspect influencing patient adherence and return to treatment, as positive patient experiences are shared within the community [34] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Soleno Therapeutics' current market position, growth expectations, and operational strategies in the rare disease sector.

Core Viewpoint - Harmony Biosciences Holdings, Inc. (HRMY) shows potential for upside based on Wall Street analysts' short-term price targets, with a mean target of $46.45 indicating a 27% upside from the current price of $36.59 [1] Price Targets and Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $8.02, indicating variability among analysts; the lowest estimate is $32.00 (12.5% decline), while the highest is $62.00 (69.5% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates - Analysts are optimistic about HRMY's earnings prospects, as indicated by a positive trend in earnings estimate revisions; the Zacks Consensus Estimate for the current year has increased by 7.4% with no negative revisions [11][12] - HRMY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside [13] Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates; thus, investors should approach price targets with skepticism [8][10] - Despite the skepticism surrounding price targets, the direction implied by them may still provide a useful guide for potential price movements [14]

Neurogene (NasdaqGM:NGNE) 2026 Conference February 12, 2026 09:00 AM ET Company ParticipantsChristine Mikail - President and CFOConference Call ParticipantsDebjit - Therapeutic AnalystDebjitMorning. Thank you for joining Guggenheim's 2026 Emerging Outlook Biotech Summit. I'm Debjit, one of the therapeutic analysts, and my next presenting company is Neurogene. From Neurogene, we have Christine Mikail, President and CFO.Christine MikailGood morning.DebjitThank you for joining us.Christine MikailGood morning, ...

产品研发进展 经济观察网 科兴生物制药股份有限公司近期在H股上市进程、创新药管线关键进展及海外市场拓展等方 面有动态更新。 高管变动 科兴制药于2025年11月向港交所主板提交H股上市申请，后续需关注港交所的审核进展、聆讯时间及最 终上市时间表。若成功上市，将拓宽公司资本通道，支持国际化战略。 公司结构与治理 股东会议争议案庭审定于2026年4月下旬至5月初进行，涉及董事会职权归属，可能影响公司治理稳定 性。此事件关联科兴生物控股层面，可能间接波及上市公司。 以上内容基于公开资料整理，不构成投资建议。 GB18注射液（GDF15单抗）针对肿瘤恶病质的国内I期临床试验于2025年10月启动入组，未来将公布安 全性、耐受性及药代动力学数据，并可能推进至后续临床阶段。该药是潜在"First-in-Class"药物，瞄准 全球未满足临床需求。其他核心管线包括聚焦炎症性肠病的GB24（TL1A/LIGHT双靶点）、针对系统 性红斑狼疮的GB19，以及三抗药物GB26，均处于早期临床阶段，未来需关注其临床试验结果与国际化 申报进展。 海外市场拓展 白蛋白紫杉醇等产品已在欧盟、阿根廷、秘鲁等多国获批，2026年将继续在拉美 ...

| | | | | | | | | | | | | 单位:股 是否 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | | | 报告期内 从公司获 | 在公 | | 姓名 | 职务 | 性 | से | 任期起始日期 | 任期终止日期 | 年初持股数 | 年末持股数 | | 年度内股份 | 增减变动 | 得的税前 | 司关 | | | | 别 | 龄 | | | | | | 增减变动量 | 原因 | | 联方 | | | | | | | | | | | | | 报酬总额 | 获取 | | | | | | | | | | | | | (力元) | | | | | | | | | | | | | | | 报酬 | | | 重事长 | | | 2021 年4月15日 | 2027年4月18日 | | | | | | | | | 邱子欣 | 总经理 | | 61 | 2021年4月15日 | 2024年1月15日 | 44.846.760 | 44.846.760 | ...

Core Viewpoint - The company focuses on the research, production, and sales of human vaccines, with a portfolio that includes 10 vaccine products targeting five infectious diseases [2] Group 1: Company Overview - The company has developed vaccines for influenza, rabies, chickenpox, shingles, and pneumonia [2] - Currently, the only product available on the market is the quadrivalent influenza virus split vaccine [2]

Core Viewpoint - JPMorgan Chase increased its stake in Innovent Biologics (01801) by acquiring 585,900 shares at a price of approximately HKD 79.23 per share, totaling around HKD 46.42 million, resulting in a new holding of approximately 87.22 million shares, representing a 5.02% ownership stake [1] Group 1 - JPMorgan Chase's acquisition of 585,900 shares indicates a strategic investment in Innovent Biologics [1] - The purchase price of HKD 79.23 per share reflects the current market valuation of Innovent Biologics [1] - The total investment amount of HKD 46.42 million signifies JPMorgan's confidence in the company's future prospects [1] Group 2 - Following the acquisition, JPMorgan's total shareholding in Innovent Biologics reached approximately 87.22 million shares [1] - The updated ownership percentage of 5.02% positions JPMorgan as a significant stakeholder in Innovent Biologics [1]

EPS创健科技(03860)发布公告，于2026年2月12日，本公司(作为买方)与卖方(作为卖方)订立协议，本公 司有条件同意收购而卖方有条件同意出售销售股份(中国基因的1,623股普通股，占中国基因已发行股本 的 16.23%)，总现金代价为4300万港元。紧随完成后，本集团于中国基因的投资将于本集团的综合财务 报表内确认为于联营公司的投资。 于本公告日期，中国基因实益拥有华新约67.68%股权。华新乃中国基因的主要营运附属公司，为一家 在中国註册成立的公司，主要从事生物制药产品的内部研发、生产及销售。其产品专注于妇科生物制药 及基因细胞治疗领域，涉及干扰素及白细胞介素的应用。近年来，中国基因集团专注于生产及销售已成 为妇科医生首选药物的"辛复宁"。 于本公告日期，本集团暂无计划或意愿于可见将来进一步收购中国基因集团的股权。 鉴于通过医疗保健和生物制药生态系统中的集成价值链可能与中国基因集团产生的业务协同效应;收购 事项为一项策略投资机会，可令本集团扩大其在中国医疗保健及生物制药行业的市场参与度;及中国基 因集团因中国医疗保健及生物制药行业发展前景向好带来的绝佳机会录得的盈利纪录及其股息政策，预 计将在完成 ...